Literature DB >> 17175127

Palliation for suspected unresectable hilar cholangiocarcinoma.

S Connor1, E Barron, D N Redhead, H Ireland, K K Madhavan, R W Parks, O J Garden.   

Abstract

AIM: The aim of this study was to evaluate the outcome of different techniques of palliation for patients with hilar cholangiocarcinoma.
METHOD: All patients treated with palliative intent between 1988 and 2004 at the Royal Infirmary of Edinburgh were reviewed. Patients were analysed on an intention to treat basis. Demographics, procedure and outcome (including re-admissions) were recorded.
RESULTS: Two hundred and thirty-three patients underwent palliative treatment for suspected hilar cholangiocarcinoma. The diagnosis was confirmed histologically in 109 patients. The procedure related morbidity and mortality was 54/225 and 18/207 respectively. Seventy-one patients required re-admission. Twenty patients underwent surgical biliary bypass for jaundice. Those undergoing surgical palliation had a longer median (95% CI) time to re-admission (16 (0-36) vs.7 (2-12) weeks, p=0.001). Endoscopic retrograde cholangio-pancreatography (ERCP) and stenting was only successful in 28 patients and was associated with a significantly higher re-admission rate compared to patients in whom ERCP was not performed (60/179 vs. 4/27, p=0.050). The overall median (95% CI) survival was 145 (124-185) days.
CONCLUSION: Current options for palliation of hilar cholangiocarcinoma provide good short term success but are all associated with significant early and late morbidity. Due to its low success and association with an increased re-admission rate, ERCP for definitive palliation should not be used in the first line staging and management of these patients.

Entities:  

Mesh:

Year:  2006        PMID: 17175127     DOI: 10.1016/j.ejso.2006.11.005

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  8 in total

1.  Low rate of active treatment of patients with hilar cholangiocarcinoma.

Authors:  A P Mishreki; E Lim; P Cranefield; S Pascoe; S Jackson; D A Stell
Journal:  Ann R Coll Surg Engl       Date:  2013-07       Impact factor: 1.891

2.  R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer.

Authors:  Wolf-Rudiger Matull; Dipok K Dhar; Lakshmana Ayaru; Neomal S Sandanayake; Michael H Chapman; Aruna Dias; John Bridgewater; George J M Webster; Jin J Bong; Brian R Davidson; Stephen P Pereira
Journal:  Liver Int       Date:  2010-09-16       Impact factor: 5.828

3.  Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study.

Authors:  Tianxiao Wang; Jiahong Dong; Yuewei Zhang; Zhizhong Ren; Ying Liu; Xiaowei Yang; Dawei Sun; Yaqin Wang
Journal:  Ann Transl Med       Date:  2022-04

4.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study.

Authors:  Jongha Park; Myung-Hwan Kim; Kyu-Pyo Kim; Do Hyun Park; Sung-Hoon Moon; Tae Jun Song; Junbum Eum; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

5.  Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study.

Authors:  Stefan Buettner; Ana Wilson; Georgios Antonis Margonis; Faiz Gani; Cecilia G Ethun; George A Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2016-04-27       Impact factor: 3.452

Review 6.  Palliation of malignant obstructive jaundice.

Authors:  G Garcea; S L Ong; A R Dennison; D P Berry; G J Maddern
Journal:  Dig Dis Sci       Date:  2008-09-04       Impact factor: 3.199

Review 7.  Hilar cholangiocarcinoma: diagnosis, treatment options, and management.

Authors:  Kevin C Soares; Ihab Kamel; David P Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

8.  Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients.

Authors:  Anthony T Ruys; Steven van Haelst; Olivier R Busch; Erik A Rauws; Dirk J Gouma; Thomas M van Gulik
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.